Immunotherapy

Another avenue of research in HRPC is immunotherapy, which is dependent on a suitable target antigen being presented to the immune system by an antigen-presenting cell (APC), such as the dendritic cell. The dendritic cell was chosen specifically because it is the most potent in eliciting a T-cell immune response. This approach has been evaluated in a randomized, placebo-controlled, phase III trial in HRPC patients with the drug APC8015. This is a product consisting of autologous dendritic cells loaded ex vivo with a recombinant fusion protein of prosta-tic acid phosphatase linked to granulocyte-macrophage colony-stimulating factor. This treatment was well tolerated and antigen-specific immunity was evident, but only in the subset of patients with a low Gleason score was there a trend toward improvement in median time to progression. A confirmatory phase III trial in these patients is now underway [53].

Vaccine-based therapies are also being evaluated. In one randomized phase II study, for example, recombinant pox viruses expressing PSA and the b7.1 co-stimulatory molecule were given to patients with nonmetastatic HRPC. Both immuno-logic activity and a delay in the development of metastatic disease at 6 months was seen [54]. Overall, targeting the immune system provides an exciting and novel approach to treating prostate cancer.

Was this article helpful?

0 0
How To Bolster Your Immune System

How To Bolster Your Immune System

All Natural Immune Boosters Proven To Fight Infection, Disease And More. Discover A Natural, Safe Effective Way To Boost Your Immune System Using Ingredients From Your Kitchen Cupboard. The only common sense, no holds barred guide to hit the market today no gimmicks, no pills, just old fashioned common sense remedies to cure colds, influenza, viral infections and more.

Get My Free Audio Book


Post a comment